Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:03:25.997Z.
Calculation as of: 2026-10-06T16:03:25.997Z.
Quote observation: 2026-10-06T15:58:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e5bf89a371f0468543faa328a941ad2f1c46577ddea7987f626d68fdce73ba7d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
HeartSciences Inc.
Market Cap
$8.03M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| HeartSciences Inc. (HSCS) | $8.03M | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.95M | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.14M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.93M | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.64M | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.23M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.53M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.34M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.23M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
